cilostazol has been researched along with Obesity in 4 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol treatment significantly induced the messenger RNA and protein expression of PCSK9 in HepG2 cells and enhanced PCSK9 promoter activity." | 5.72 | Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. ( Chang, HY; Chao, TH; Chen, PW; Lee, CH; Tseng, SY, 2022) |
| " Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up." | 2.78 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013) |
| "Intermittent claudication is a form of exercise intolerance characterized by muscle pain during walking in patients with peripheral artery disease (PAD)." | 1.40 | Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. ( Alcantara, R; Baltgalvis, KA; Claypool, MD; Friera, AM; Godinez, G; Goff, D; Gururaja, T; Hansen, D; Hitoshi, Y; Jenkins, Y; Kinsella, TM; Lang, W; Lau, D; Li, W; Li, Y; Markovtsov, V; McCaughey, K; McLaughlin, J; Nguyen, H; Pan, A; Park, G; Payan, DG; Shaw, SJ; Singh, BK; Singh, R; Smith, IJ; Sun, TQ; Uy, G; White, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PW | 1 |
| Tseng, SY | 1 |
| Chang, HY | 1 |
| Lee, CH | 1 |
| Chao, TH | 1 |
| Wada, T | 1 |
| Onogi, Y | 1 |
| Kimura, Y | 1 |
| Nakano, T | 1 |
| Fusanobori, H | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Baltgalvis, KA | 1 |
| White, K | 1 |
| Li, W | 1 |
| Claypool, MD | 1 |
| Lang, W | 1 |
| Alcantara, R | 1 |
| Singh, BK | 1 |
| Friera, AM | 1 |
| McLaughlin, J | 1 |
| Hansen, D | 1 |
| McCaughey, K | 1 |
| Nguyen, H | 1 |
| Smith, IJ | 1 |
| Godinez, G | 1 |
| Shaw, SJ | 1 |
| Goff, D | 1 |
| Singh, R | 1 |
| Markovtsov, V | 1 |
| Sun, TQ | 1 |
| Jenkins, Y | 1 |
| Uy, G | 1 |
| Li, Y | 1 |
| Pan, A | 1 |
| Gururaja, T | 1 |
| Lau, D | 1 |
| Park, G | 1 |
| Hitoshi, Y | 1 |
| Payan, DG | 1 |
| Kinsella, TM | 1 |
| Gao, W | 1 |
| Zhang, Q | 1 |
| Ge, H | 1 |
| Guo, Y | 1 |
| Zhou, Z | 1 |
1 trial available for cilostazol and Obesity
| Article | Year |
|---|---|
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H | 2013 |
3 other studies available for cilostazol and Obesity
| Article | Year |
|---|---|
Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
Topics: Animals; Cilostazol; Lipids; Mice; Mice, Obese; Obesity; PPAR gamma; Proprotein Convertase 9; Propro | 2022 |
Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cilostazol; Diabetes Mellitus, E | 2013 |
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Arginine; Cilostazol; Diet, High-F | 2014 |